| ￥2600 | |
| Z06450-100 | |
|
|
|
|
|
|
|
|
|
| Species | Varicella-zoster virus (strain Oka vaccine) | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 58.39 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) is greater than 95% as determined by SEC-HPLC. »
Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen. |
| Synonyms | Envelope glycoprotein E; gE; ORF68; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
